Parexel on the Pulse: EU Clinical Trial Regulation (CTR)

Paul Bridges on the EU Clinical Trial Regulation (CTR)

Return to Insights Center

Related Insights

Blog

Hello again! ICH Q5A revision 2 updates guidance for developers of biotechnological products and ATMPs

Mar 21, 2024

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Video

On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Article

EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022